Tom Miller Joins KEW Group as Independent Director
Cambridge, Mass., Apr. 1, 2015 – KEW Group Inc. (KEW), a privately held oncology services company, today announced that Thomas (Tom) J. Miller, Jr. has joined its Board of Directors as an independent director. A seasoned executive in the diagnostic space, Mr. Miller previously served as Chief Executive Officer (CEO) of Siemens Healthcare’s Customer Solutions Division, responsible for an organization of 26,000 employees in over 130 countries. He also held other leadership roles during his tenure at Siemens, including serving as a member of the Group Board of Siemens Medical Solutions, as well as overseeing the company’s global MRI business.
“We are thrilled to welcome Tom to our Board and look forward to leveraging his tremendous experience, expertise and insights to support KEW’s diagnostics and healthcare informatics,” said Scott Schell, PhD, MD, MBA, KEW’s President and CEO. “We believe Tom will provide our company with crucial strategic and operational guidance to further enhance our commercialization and expansion activities in the coming months.”
In addition to his leadership roles with Siemens, Mr. Miller has served as CEO for several other organizations, including Global Medical Operations of Carl Zeiss, Inc.; Analogic Corporation; and LightLab Imaging, a start-up he helped to establish and sell, and for whom he also served as Chairman. In April 2013, he founded GreyBird Ventures, a consultancy and investment firm, where he currently serves as director, advisor, and/or investor in six healthcare start-up companies. Mr. Miller received his B.S. in Nuclear Engineering from the University of Massachusetts, and received his Masters of Science degree from the Harvard-MIT Program in Health Sciences and Technology.
“KEW and CancerPlex represent the future of molecular genetic diagnostics for cancer, and a critical key for helping patients access precision therapies to personalize their cancer treatments,” said Mr. Miller. “I’m excited to be part of this next stage of KEW’s growth and development, and look forward to supporting collaborations with payers, diagnostic providers, hospital systems, and pharmaceutical companies.”
CancerPlex gives oncologists practical information to identify action-oriented solutions by coupling comprehensive, patient-specific, genomic data with evidence-based clinical intelligence about approved and emerging therapies. Oncologists use this information to create treatment decisions and optimize care in ways that are unique to each patient. KEW’s CancerPlex is one of the most comprehensive genetic/genomic tests available for accurate, thorough, and timely molecular diagnosis of solid tumors. Encompassing over four hundred cancer genes, CancerPlex identifies changes in cancer genes which can be treated by new, precision therapies, requiring tumor samples smaller than other next-generation sequencing tests.
With 80 percent of U.S. cancer patients now treated in the community oncology setting, KEW’s specific focus on serving community oncology practices underscores the company’s mission to ensure that all patients have access to the most current, personalized treatment options, improved treatment outcomes, and better quality of life.